Bridge Creek Capital Management LLC Acquires 3,297 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Bridge Creek Capital Management increased its stake in Zimmer Biomet Holdings, Inc. by 12.3%, acquiring an additional 3,297 shares during the second quarter, bringing its total holdings to 30,133 shares valued at approximately $2.748 million.
• Several major investors have also boosted their positions in Zimmer Biomet, with 88.89% of the stock now owned by institutional investors.
• Zimmer Biomet reported earnings that exceeded expectations with $2.07 EPS for the most recent quarter, alongside setting its FY 2025 earnings guidance at 8.100-8.300 EPS.

Bridge Creek Capital Management LLC lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 12.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,133 shares of the medical equipment provider's stock after buying an additional 3,297 shares during the quarter. Bridge Creek Capital Management LLC's holdings in Zimmer Biomet were worth $2,748,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ZBH. Garde Capital Inc. bought a new position in Zimmer Biomet in the first quarter valued at about $29,000. Menard Financial Group LLC bought a new position in Zimmer Biomet during the fourth quarter worth about $30,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet during the first quarter worth about $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet during the first quarter worth about $30,000. Finally, Accent Capital Management LLC bought a new position in Zimmer Biomet during the first quarter worth about $35,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Down 0.2%

Shares of NYSE:ZBH traded down $0.18 during trading on Friday, hitting $100.03. 4,228,497 shares of the company were exchanged, compared to its average volume of 1,180,396. The stock has a market cap of $19.82 billion, a price-to-earnings ratio of 24.34, a P/E/G ratio of 2.30 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72. The firm has a fifty day moving average price of $100.06 and a two-hundred day moving average price of $99.39. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet's payout ratio is 23.36%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. UBS Group raised their price target on Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Stifel Nicolaus raised their price target on Zimmer Biomet from $115.00 to $118.00 and gave the stock a "buy" rating in a research report on Friday. Rothschild Redb raised Zimmer Biomet to a "strong-buy" rating in a research report on Thursday. Rothschild & Co Redburn began coverage on Zimmer Biomet in a research report on Thursday. They set a "buy" rating and a $130.00 price target on the stock. Finally, Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $113.16.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.